+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysis

Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysis

RadioTherapy and Oncology 84(2): 140-147

Purpose: To compare the visibility of different manufacturers I-125, seeds, and to investigate the effect of differences in dosimetry on treatment planning.Materials and methods: Oncura Oncoseed, Oncura Echoseed, IBT Intersource, Bebig Isoseed and Nucletron Selectseed were investigated. The point dose at increasing distances from each seed type was calculated for three different angles; theta = 0 degrees, 45 degrees and 90 degrees (where theta = 0 degrees lies parallel to seed length). 10 patient plans were used to assess the effect of a change in dosimetry on treatment planning and quality of prostate and rectum implant indices such as Vp100, Vp200, Dp90, V000 and Vr69. All implant indices and dosimetry data were compared to Oncoseed. Visibility under X-ray, fluoroscopy, CT and MR1 was investigated using prostate phantoms created in-house. Statistical significance was calculated using paired two-tailed t-tests.Results: Dosimetric analysis was carried out for seeds of the same source strength. Differences in dose increase closer to the centre of each source, with the largest changes occurring for the angle theta = 0 degrees. Selectseed and Isoseed seed types provide a consistently lower dose in all three directions. Changes to Vp100 are small and statistically insignificant for all seeds except Selectseed which shows a statistically significant decrease of 0.04% (p = 0.02). Changes to Vp 150 and Vp200 are statistically significant (p < 0.01), with Intersource showing the greatest increase in both values. Selectseed shows a decrease in both Vp150 and Vp200. Echoseed shows an increase in both Vp150 and Vp200. Changes to D90 are statistically significant (p < 0.01), with Intersource showing the greatest increase, followed by Isoseed then Echoseed. Selectseed shows a decrease in D90. For Vr100 there is no statistically significant change for any seed type. However, all seeds except Selectseed show a statistically significant increase in the value of Vr69, with Intersource showing the greatest increase. On fluoroscopy and X-ray images, Intersource seeds appear least visible, Echoseed and Oncoseed are similar, and Isoseed and Selectseed are most visible. Ultrasound greyscale beam profiles show that all seed images have a FWHM larger than the Oncoseed image. The CT greyscale beam profiles are similar for all seed images. The MRI signal voids are similar for all seed images except Intersource which shows a larger signal void.Conclusions: The greatest changes to point dose occur at very close distances to the seeds. Changing seed type may require a treatment replan to maintain satisfactory DVH criteria. Visibility on US and CT is similar, though it may vary on MRI, X-ray and fluoroscopy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052269609

Download citation: RISBibTeXText

PMID: 17588696

DOI: 10.1016/j.radonc.2007.05.023

Related references

Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry. Physics in Medicine and Biology 52(11): 3105-3119, 2007

Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis. Journal of Clinical Oncology 23(16_suppl): 4558-4558, 2016

Comparison of 3 different postimplant dosimetry methods following permanent 125I prostate seed brachytherapy. Medical Dosimetry 38(3): 309-314, 2014

Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry. BrachyTherapy 6(1): 9-15, 2007

Prostate brachytherapy postimplant dosimetry: a comparison of suture-embedded and loose seed implants. BrachyTherapy 5(3): 165-173, 2006

Measurement uncertainty analysis of low-dose-rate prostate seed brachytherapy: post-implant dosimetry. Australasian Physical & Engineering Sciences in Medicine 38(1): 71-81, 2015

Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. BrachyTherapy 3(1): 10-19, 2004

Seed-based transrectal ultrasound-fluoroscopy registration method for intraoperative dosimetry analysis of prostate brachytherapy. Medical Physics 35(3): 840-848, 2008

Decline of dose coverage between intraoperative planning and post implant dosimetry for I-125 permanent prostate brachytherapy: comparison between loose and stranded seed implants. RadioTherapy and Oncology 91(2): 202-206, 2008

Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy. Journal of Radiation Research 57(1): 68-74, 2015

Evaluation of the correlation between implant dosimetry and post implant dosimetry using CT and MRI in the treatment of early prostate cancer with I-125 permanent seed brachytherapy. 2007

An Unusual Triple-Decker Variant of the Tetragonal BaAl4-Structure Type: Synthesis, Structural Characterization, and Chemical Bonding of Sr3Cd8Ge4 and Eu3Cd8Ge4. Inorganic Chemistry, 2017

Improvements in prostate brachytherapy dosimetry due to seed stranding. BrachyTherapy 6(1): 44-48, 2007